While Canopy Growth Corp (NYSE: CGC) has announced strategic changes that could help lower its cost burden, the company is “sized for growth” that may not materialize in the medium-term, according to MKM Partners.
The Canopy Growth Analyst
Bill Kirk maintained a Neutral rating on Canopy Growth and reduced the price target from CA$21 ($15.56) to CA$19 ($14.08).
The Canopy Growth Thesis
Canopy Growth reported sequential deceleration in revenue and a wider EBITDA loss for the fiscal fourth quarter, while most peers announced sequential improvements, Kirk said in a Thursday note. (See his track record here.)
Canopy Growth identified certain strategic and organizational changes, like facilities closures, market exits and layoffs, which may reduce its cost burden, the analyst said.
Yet the company is too large for the current environment and continues to cultivate much more than it can sell, he said.
Kirk further said that Canopy Growth may not make much progress on the adjusted EBITDA front in fiscal 2021, given low-priced and lower -margin value offerings being the primary growth opportunity.
“Upside in Canopy shares is more likely via legislative changes/excitement than operational improvement.”
CGC Price Action
Shares of Canopy Growth had declined a little over 1% to $16.35 at the time of publication Thursday.
Aphria, Aurora Analyst Says Buy The Dip To Take Advantage Of Cannabis Stock Sell-Off
Cannabis Countdown: Top 10 Marijuana And Psychedelic Stock News Stories Of The Week
Latest Ratings for CGC
|Feb 2020||Stifel Nicolaus||Maintains||Buy|
|Jan 2020||BMO Capital||Upgrades||Market Perform||Outperform|
|Nov 2019||Bank of America||Upgrades||Neutral||Buy|
View More Analyst Ratings for CGC
View the Latest Analyst Ratings
See more from Benzinga
- Aphria, Aurora Analyst Says Buy The Dip To Take Advantage Of Cannabis Stock Sell-Off
- Aphria, Aurora Among Top Performers As Canadian Cannabis Sales Spike
- Canopy Growth Set To Become Cannabis Sector Leader, Says BofA
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.